The purpose of this pivotal study is to illustrate the safety and effectiveness of the StimGuard Sacral Nerve Stimulation (SNS) System in the treatment refractory urge incontinence. This is a prospective, randomized, controlled, multi-center, study in which 92 subjects will receive a StimGuard SNS System.
The StimGuard SNS System is utilized for the treatment of refractory urgency urinary incontinence as defined by the International Continence Society (ICS) Standardization of Terminology Committees Joint Report as the observation of involuntary leakage from the urethra synchronous with the sensation of a sudden, compelling desire to void that is difficult to defer. The system provides treatment by delivering small controlled electrical pulses to the sacral nerves, as these nerves have been shown to regulate the micturition cycle. In this study, subjects will be randomized into one of two groups with a 1:1 ratio after enrollment. Subjects will either be randomized to an immediate or a delayed activation group. An intraoperative test will be performed, and all subjects will receive a permanent implant if they have an appropriate motor nerve root response without significant discomfort at 5 mA amplitude or less.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
Beaumont Hospital
Royal Oak, Michigan, United States
Reduction in number of urge related incontinence episodes
Self reported on a 3-day voiding diary
Time frame: 3 Months
Incidence and severity of adverse events
Time frame: Up to 12 months
Proportion of subjects with a reduction in the degree of urgency as measured by PPIUS
Self reported on a 3-day voiding diary
Time frame: 3 Months
Proportion of subjects with a reduction in the number of voids compared to baseline
Self reported on a 3-day voiding diary
Time frame: 3 Months
Improved quality of life function via the Incontinence Quality of Life Scale (I-QOL)
Quesionnaire
Time frame: 3 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.